Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.66 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.66 |
| ▸ | CA1 | P00915 | 2/20 | 0.66 |
| ▸ | CA2 | P00918 | 2/20 | 0.66 |
| ▸ | GABRP | O00591 | 2/20 | 0.66 |
| ▸ | GABRD | O14764 | 2/20 | 0.66 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.66 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.66 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.66 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.66 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.66 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.66 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.66 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.66 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.66 |
| ▸ | GABRE | P78334 | 2/20 | 0.66 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.66 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.66 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6581929 | 0.90 | APP (0.63) | MAOBKCNA5KCNH2CA1CA2 | |
| SCHEMBL11733704 | 0.88 | KCNA5 (0.62) | MAOBKCNA5KCNH2CA1CA2 | |
| SCHEMBL14833013 | 0.87 | APP (0.82) | MAOBKCNA5KCNH2APPNPC1 | |
| SCHEMBL29873198 | 0.87 | APP (0.82) | MAOBKCNA5KCNH2APPNPC1 | |
| SCHEMBL11733647 | 0.83 | MAOB (0.67) | MAOBKCNA5KCNH2APPNPC1 | |
| SCHEMBL11646027 | 0.82 | MAOB (0.61) | MAOBKCNA5KCNH2CA1CA2 | |
| SCHEMBL1143874 | 0.81 | GABRP (0.66) | MAOBKCNA5KCNH2GABRPGABRD | |
| SCHEMBL4235410 | 0.81 | ESR1 (0.73) | MAOBKCNA5KCNH2APPNPC1 | |
| SCHEMBL13672844 | 0.81 | APP (0.64) | MAOBKCNA5KCNH2GABRPGABRD | |
| SCHEMBL3922788 | 0.81 | APP (0.64) | MAOBKCNA5KCNH2GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009009417-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-15 | — | — | WO | claimed |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-08 | — | — | US | claimed |
| US-20050038107-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | WYETH | 2005-02-17 | — | — | US | claimed |
| EP-1458700-A2 | SUBSTITUTED 2-PHENYL BENZOFURANS AS ESTROGENIC AGENTS | Wyeth (US) | 2004-09-22 | — | — | EP | claimed |
| US-20030171428-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | WYETH | 2003-09-11 | — | — | US | claimed |
| WO-2003051860-A2 | SUBSTITUTED 2-PHENYL BENZOFURANS AS ESTROGENIC AGENTS | WYETH (US) | 2003-06-26 | — | — | WO | claimed |
| WO-2009009417-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-08 | — | — | US | disclosed |
| EP-1458700-B1 | SUBSTITUTED 2-PHENYL BENZOFURANS AS ESTROGENIC AGENTS | WYETH CORP (US) | 2008-12-03 | — | — | EP | disclosed |
| US-7173061-B2 | Compounds for imaging alzheimer's disease | GE HEALTHCARE LIMITED (GB) | 2007-02-06 | — | — | US | disclosed |
| US-7173061-B2 | Compounds for imaging alzheimer's disease | GE HEALTHCARE LIMITED (GB) | 2007-02-06 | — | — | US | disclosed |
| US-7173061-B2 | Compounds for imaging alzheimer's disease | GE HEALTHCARE LIMITED (GB) | 2007-02-06 | — | — | US | disclosed |
| US-20060074128-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | WYETH (US) | 2006-04-06 | — | — | US | disclosed |
| EP-1266897-A2 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6410562-B1 | ANTIDIABETIC AGENTS | ELI LILLY AND COMPANY | 2002-06-25 | — | — | US | disclosed |
| WO-1999032482-A1 | HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| EP-0924209-A1 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 1999-06-23 | — | — | EP | disclosed |
| US-4024273-A | Coronary vasodilator and anti-anginal compositions comprising substituted benzofurans and benzothiophenes and methods of producing coronary vasodilation and anti-anginal activity | SMITHKLINE CORPORATION (US) | 1977-05-17 | — | — | US | disclosed |
| US-4001426-A | HAVING CORONARY VASODILATOR ACTIVITY | SMITHKLINE CORPORATION (US) | 1977-01-04 | — | — | US | disclosed |
| US-3947470-A | CORONARY VASODILATORS, TREATMENT OF ANGINA PECTORIS | SMITHKLINE CORPORATION (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074128-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | ESR1, ESR2, GPER1 | MAOB 2560/4885KCNA5 1000/4885KCNH2 2672/4885 |
| US-20050038107-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | ESR1, ESR2, ESRRA | MAOB 2275/4885KCNA5 992/4885KCNH2 2576/4885 |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | COL2A1, COL1A1, COL14A1 | MAOB 1657/4885KCNA5 4177/4885KCNH2 4367/4885 |
| US-20030171428-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | ESR1, ESR2, GPER1 | MAOB 2350/4885KCNA5 1061/4885KCNH2 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.